Search

Displaying results 2471 - 2480 of 10000 in total
  1. Drug

    Cedazuridine

    go.drugbank.com/drugs/DB15694
    ApprovedInvestigational

    [A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by … Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated

  2. Drug

    Botulinum toxin type A

    go.drugbank.com/drugs/DB00083
    ApprovedInvestigational

    In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. … [A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm

    Categories: Botulinum Toxins, Type ASynonyms: BTX A, BTX-A
  3. Drug

    Enoxaparin

    go.drugbank.com/drugs/DB01225
    ApprovedInvestigational

    Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. … Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.

    Products: ENOX 10000 ANTI-XA IU/1ML KULLANIMA HAZIR ENJEKTOR, 2 ADET, ENOX 10000 ANTI-XA IU/1ML KULLANIMA HAZIR ENJEKTOR, 20 ADET
  4. Drug

    Toremifene

    go.drugbank.com/drugs/DB00539
    ApprovedInvestigational

    Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. … [A256928] Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however

  5. Drug

    Aminophylline

    go.drugbank.com/drugs/DB01223
    ApprovedInvestigational

    Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. … Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator.

    Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  6. Drug

    Erdosteine

    go.drugbank.com/drugs/DB05057
    ApprovedInvestigational

    Erdosteine is a drug that causes a breakdown of mucus, also known as a _mucolytic_ agent. … It is a _thiol_ derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic bronchitis.

  7. Drug

    Iloperidone

    go.drugbank.com/drugs/DB04946
    ApprovedInvestigational

    Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. … [A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors

  8. Drug

    Clascoterone

    go.drugbank.com/drugs/DB12499
    ApprovedInvestigational

    [A218846] In August 2020, FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and female patients 12 years and older. … [L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766]

  9. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    This decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer. … In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets

  10. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … [A251770] Allogeneic hematopoietic-cell transplantation would be a therapeutic option in patients with β-thalassemia; however, this process is reserved for young children with an HLA-identical sibling

    Categories: Complex MixturesSynonyms: Autologous CD34+ cells encoding βA-T87Q-Globin gene